RT Journal Article
SR Electronic
T1 Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate
JF Evidence Based Medicine
JO Evid Based Med
FD BMJ Publishing Group Ltd
SP 215
OP 216
DO 10.1136/ebmed-2017-110721
VO 22
IS 6
A1 Graziella Filippini
YR 2017
UL http://ebm.bmj.com/content/22/6/215.abstract
AB